Neuroone Medical Technologies CORP 8-K filings

NeuroOne Medical Technologies Corporation announced a 16% year-over-year increase in product revenue to $2.0 million for its third fiscal quarter ended June 30, 2026, alongside a significant expansion in gross margins to 59.9%.

NeuroOne Medical Technologies Corporation has filed a prospectus supplement to sell up to $13.4 million of common stock through an existing at-the-market program.

NeuroOne Medical Technologies Corporation announced fiscal Q2 2026 results, showcasing a 72% year-over-year product revenue increase to $2.4 million and significant clinical progress with its OneRF Trigeminal Nerve Ablation System.

NeuroOne Medical Technologies Corporation announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the deficiency matter.

NeuroOne Medical Technologies Corporation announced the retirement of its Chief Financial Officer, Ronald McClurg, effective June 30, 2026, with COO Christopher Volker set to assume the CFO role.

NeuroOne Medical Technologies Corporation is implementing a 1-for-6 reverse stock split, effective April 15, 2026, to adjust its issued and outstanding shares of common stock.

NeuroOne Medical Technologies Corporation held its Annual Meeting on April 3, 2026, where stockholders approved amendments to the equity incentive plan and authorized a reverse stock split.

NeuroOne Medical Technologies Corporation announced the date for its 2026 annual meeting of stockholders and the corresponding deadline for stockholder proposals.

NeuroOne Medical Technologies Corporation reported its first quarter fiscal year 2026 financial results, showing a net loss but projecting at least $10.5 million in product revenue for fiscal year 2026, a 17% increase.

NeuroOne Medical Technologies Corporation announced the appointment of seasoned med-tech executive and analyst Jason Mills to its Board of Directors, effective December 18, 2025.

NeuroOne Medical Technologies Corporation reported robust financial results for fiscal year 2025, driven by significant product revenue growth and improved gross margins.

NeuroOne Medical Technologies Corporation has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement.

NeuroOne Medical Technologies Corporation announced preliminary unaudited fiscal year 2025 product revenue of $9.1 million, marking a 163% increase from the prior year, alongside $6.6 million in cash and cash equivalents.

NeuroOne Medical Technologies Corporation announced FDA 510(k) clearance for its OneRF Trigeminal Nerve Ablation System for pain treatment and functional neurosurgical procedures.

NeuroOne Medical Technologies Corporation filed an updated prospectus supplement to offer and sell up to $6.75 million of common stock through its existing at-the-market program.

NeuroOne Medical Technologies Corporation reported strong third-quarter fiscal year 2025 financial results, with product revenue increasing 105% year-over-year and gross margin expanding significantly, alongside a successful $8.2 million capital raise.

NeuroOne Medical Technologies Corporation announces improved financial results for Q2 fiscal year 2025 and the filing of an FDA submission for its OneRF Trigeminal Nerve Ablation System.

NeuroOne Medical Technologies Corporation received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for continued listing.

NeuroOne Medical Technologies successfully closes a public offering of 16,000,000 shares at $0.50 per share, raising approximately $8 million for general working capital.

NeuroOne Medical Technologies Corporation's stockholders approved the 2025 Equity Incentive Plan at the annual meeting on February 14, 2025.

NeuroOne Medical Technologies Corporation held its annual meeting on February 14, 2025, where stockholders approved several key proposals, including a reverse stock split and a new equity incentive plan.

NeuroOne announces a significant increase in product revenue and gross profit for Q1 2025, fueled by its expanded agreement with Zimmer Biomet.

NeuroOne Medical Technologies Corporation has regained compliance with Nasdaq's minimum share price requirements, averting a potential delisting.

NeuroOne Medical Technologies published a letter to shareholders on January 14, 2025, outlining the company's achievements, progress, and strategy for value creation.

NeuroOne Medical Technologies Corporation has received a delisting notice from Nasdaq after failing to maintain a minimum bid price of $1.00 per share.

NeuroOne Medical Technologies Corporation reports a record $6.2 million in preliminary unaudited revenue for the first quarter of fiscal year 2025, driven by a significant increase in product revenue and a one-time collaboration payment.

NeuroOne Medical Technologies Corporation announced a 77% increase in product revenue for fiscal year 2024 and anticipates substantial growth in 2025, driven by an expanded partnership with Zimmer Biomet.

NeuroOne Medical Technologies Corporation and Growth Opportunity Funding, LLC mutually agreed to terminate their Loan and Security Agreement, with no outstanding loan balance.

NeuroOne Medical Technologies Corporation and Zimmer Biomet have expanded their distribution agreement, granting Zimmer Biomet exclusive rights to distribute NeuroOne's OneRF Ablation System in the US and certain international markets.

NeuroOne Medical Technologies has amended employment agreements with its executive officers to revise severance benefits in the event of a change in control.